Skip to main content
Parmax Pharma Limited logo

Parmax Pharma Limited — Investor Relations & Filings

Ticker · 540359 ISIN · INE240T01014 LEI · 335800838LWBPQU5MJ05 BSE.NS Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-05-30 Regulatory Filings
Country IN India
Listing BSE.NS 540359

About Parmax Pharma Limited

https://www.parmaxpharma.com/

Parmax Pharma Limited specializes in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical formulations. The company’s product range encompasses various delivery systems, including solid orals like tablets and capsules, as well as liquid preparations and topical ointments. Its therapeutic focus spans several categories, such as anti-infectives, analgesics, gastrointestinal agents, and respiratory medications. The organization maintains a commitment to stringent quality control measures and adheres to Good Manufacturing Practices (GMP) to ensure product safety and therapeutic effectiveness. By leveraging advanced production facilities and a comprehensive distribution infrastructure, the company provides healthcare solutions across multiple markets. Its core operations prioritize formulation research and the scaling of manufacturing processes to meet diverse clinical requirements.

Recent filings

Filing Released Lang Actions
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for ....
Regulatory Filings Classification · 65% confidence The document is a stock exchange filing notifying the rescheduling of a Board of Directors meeting to consider audited financial results. It does not include any substantive financial data and is essentially an exchange announcement per SEBI Listing Regulations. It is not a full report, earnings release, proxy statement, or management change notice, but rather a routine regulatory disclosure. Thus, it falls under the generic Regulatory Filings (RNS) category.
2026-05-30 English
Scrutinizer Report
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a submission to the stock exchange under SEBI LODR Regulation 44(3) and Companies Act provisions, providing detailed voting results of an Extraordinary General Meeting along with the Scrutinizer’s Report. It enumerates vote counts ‘in favour’, ‘against’, and invalid/abstained for multiple resolutions and formally lodges the voting outcome. This is precisely an official declaration of voting results from a shareholder meeting, matching the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-28 English
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve audited financial results of ....
Regulatory Filings Classification · 80% confidence The document is a notice to the stock exchange under SEBI Listing Regulation 29, informing of a forthcoming Board of Directors meeting to approve audited financial results and closure of the trading window. It does not contain financial results, management changes, or actual report data—it’s a regulatory announcement/notice. This fits the fallback category “Regulatory Filings” (RNS).
2026-05-27 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.